Actively Recruiting
Safety of Transmucosal Capsaicin Sphenopalatine Ganglion Stimulation in Acute Ischemic Stroke
Led by Instituto Mexicano del Seguro Social · Updated on 2026-02-17
46
Participants Needed
1
Research Sites
60 weeks
Total Duration
On this page
Sponsors
I
Instituto Mexicano del Seguro Social
Lead Sponsor
C
Centenario Hospital Miguel Hidalgo
Collaborating Sponsor
AI-Summary
What this Trial Is About
This study will evaluate the safety and tolerability of a dissolvable oral film containing a very small dose of capsaicin (the compound that produces the "hot" sensation in chili peppers) in adults with acute ischemic stroke. The film is designed to stimulate nerves in the mouth that may activate the sphenopalatine ganglion, a structure involved in regulating blood flow to the brain. The main purpose of this study is to determine whether the capsaicin film can be given safely to patients with acute ischemic stroke when started within 24 hours of symptom onset. Participants will be randomly assigned (like flipping a coin) to receive either the capsaicin oral film or a placebo film that looks and tastes similar but contains no capsaicin. Neither the participants nor the clinical team will know which film is given (double-blind). All participants will continue to receive standard medical care for acute ischemic stroke. After administration of the study film, participants will be closely monitored for side effects and changes in vital signs (blood pressure, heart rate, respiratory rate, temperature, and oxygen saturation) at prespecified time points up to 72 hours. The primary outcome is the frequency of adverse events related to the study product within 72 hours after treatment begins. Participants will also be followed clinically up to 3 months as part of usual stroke care. The results of this study will help determine whether this approach is safe and feasible, and whether further studies are warranted.
CONDITIONS
Official Title
Safety of Transmucosal Capsaicin Sphenopalatine Ganglion Stimulation in Acute Ischemic Stroke
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age between 18 and 80 years
- NIH Stroke Scale score between 6 and 20 at screening
- Stroke symptom onset within 24 hours before study intervention
- Pre-stroke modified Rankin Scale score of 1 or less
- Written informed consent provided by participant or legally authorized representative
You will not qualify if you...
- Intracranial hemorrhage found on brain imaging
- Severe consciousness impairment making participation unsafe
- Blood pressure persistently higher than 220/120 mmHg after initial treatment
- Severe systemic disease that may affect participation or safety according to investigator
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Centenario Hospital Miguel Hidalgo
Aguascalientes, Aguascalientes, Mexico, 20000
Actively Recruiting
Research Team
J
Juan M Marquez-Romero, MD, PhD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
DOUBLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here